The use of computer technologies at the preclinical stage of hepatotoxicity assessment of antiviral drug riamilovir

Despite the fact that riamilovir is already used in clinical practice for influenza treatment in the territory of the Russian Federation, it can be used as broad-spectrum potential antiviral because chemically it is a nucleotide analog. This article provides the analysis of experimental data from a preclinical investigation of riamilovir's hepatotoxicity. At this stage of a preclinical study in vivo experiment was used on guinea pigs and computer modeling of ADMET profile and molecular docking of riamilovir with potential target N-domain HSP90α. According to the experimental data, riamilovir can cause macro- and microvesicular steatosis and decrease of total cholesterol levels, this can be explained by HSP90α inhibition and subsequent mitochondrial dysfunction which leads to increasing of fat accumulation in the liver.